Vitrolife SRL
5.0 FTEVitrolife reported total assets of €2.25m at the end of the 2025 financial year (annual accounts filed with the NBB on 06 Aug 2026), with 5 full-time equivalents.
The score of Vitrolife shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +101 % Total assets +68 % Headcount (avg FTE) +67 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Vitrolife's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 22 Aug 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 24 Aug 2022
Vitrolife's financial analysis
- Solvency46.6%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Vitrolife
Vitrolife's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0685.675.182
- VAT number
- BE0685675182
- Peppol
- Registered · 0208:0685675182 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 06 Dec 2017
- Registered office
- 1840 Londerzeel
- Size
- Micro · 5.0 FTE
- Latest accounts
- 2025 · filed on 06 Aug 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Vitrolife (SRL) has been based in Londerzeel since 2017, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 167,338 € and equity of €1.05m; its revenue is not published. With 5.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 46.6%, above the median of its sector (46.0%).
Companies similar to Vitrolife
Companies in the same business, of comparable size and area, outside its group.
- Fagron Compounding Services Wholesale of pharmaceutical and medical goods Bornem · balance sheet €2.66m
- Endoceutics Wholesale of pharmaceutical and medical goods Brussels · balance sheet €3.45m
- Launchpad Europe Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet 120,635 €
- Maimonides Wholesale of pharmaceutical and medical goods Antwerp · balance sheet 142 €
- Biocon Biologics Belgium Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €1.09m
- Wimeq Wholesale of pharmaceutical and medical goods Heusden-Zolder · balance sheet 48,978 €
- MiniMed Belgium Wholesale of pharmaceutical and medical goods Brussels · balance sheet 8,076 €
- Nadimed Wholesale of pharmaceutical and medical goods Kontich · balance sheet €2.27m
Frequently asked questions about Vitrolife
What is the revenue of Vitrolife?
Vitrolife files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Vitrolife?
In Belgium, the VAT number is the company number prefixed with BE: BE0685675182 for Vitrolife, if the company is VAT-registered. Its company number (CBE) is 0685.675.182.
Where is the registered office of Vitrolife?
According to the CBE register, the registered office of Vitrolife is in 1840 Londerzeel.
What is the equity of Vitrolife?
At the close of the 2025 financial year, the equity of Vitrolife amounts to 1,047,788 €, a solvency of 46.6% of total assets.
How many people work at Vitrolife?
5.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Vitrolife?
The register lists 1 active mandates at Vitrolife. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Vitrolife
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →